You are here: Industry Insights > Pfizer

News List

Biogen to Acquire from Pfizer First-in-Class Phase 2b Ready Asset for Cognitive Impairment Associate biospace
March 13, 2018
Biogen Inc. (Nasdaq: BIIB) announced today an agreement to acquire from Pfizer Inc. (
Biogen Buys Pfizer's PhII-ready Schizophrenia Asset biospace
March 13, 2018
Biogen is buying Pfizer’s PF-04958242, a first-in-class, Phase IIb-ready drug to treat several neurological and psychiatric diseases, including schizophrenia.
US panel backs Pfizer’s Xeljanz for ulcerative colitis pharmatimes
March 12, 2018
US regulatory advisors are backing use of Pfizer’s JAK inhibitor Xeljanz to treat adults with moderately to severely active ulcerative colitis (UC).
Pfizer eyes gastro use for Xeljanz after thumbs-up from FDA advisers pharmaphorum
March 12, 2018
Pfizer has been steadily building a franchise around its inflammatory diseases pill, Xeljanz (tofacitinib) over the last few years, and it could add another use after US experts recommended a licence in ulcerative colitis.
Pfizer Terminates PDC Agreement with CytomX Therapeutics biospace
March 09, 2018
CytomX Therapeutics, Inc，this week Pfizer Inc. notified the Bay Area-based company of its intent to terminate its five-year-old oncology collaboration.
Pfizer Invites Public to View and Listen to Webcast of Pfizer Presentation at Healthcare Conference biospace
March 08, 2018
Pfizer Invites Investors and the Public Invite to Watch and Listen Global President and Oncologist Andy Bumpers and Senior Vice President Chris Boshoff, Head of Immunology Oncology, Early Development and Translational Oncology, Online Presentation
Pfizer to include ceratin brands for consumer health biz expressbpd
March 02, 2018
The review will consider a range of options, including a full or partial separation of the consumer healthcare business from Pfizer through a spin-off, sale or other transaction
Pfizer could face £502M bill if it comes up short in U.K. patent appeal for Lyrica fiercepharma
February 27, 2018
The company could be on the hook for £502 million ($700 million) in government spending on the branded med, according to a new study.
China’s DL Medicine forms research alliance with Pfizer pharmaceutical-technology
February 09, 2018
China-based biotechnology firm NetVation DL Medicine has formed a two-year research partnership with Pfizer for the discovery and development of new drug candidates.
ICMR, Pfizer to work on antimicrobial resistance expressbpd
February 01, 2018
The Indian Council of Medical Research (ICMR) and Pfizer has announced that they will set up a centre to address the growing threat of antimicrobial resistance in India.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 83 84 Next page